Amgen’s Enbrel Patents Upheld, Copycat from Novartis Denied
Amgen’s drug patent upheld and Novartis’s copycat version is denied.
Sara is a credited freelance writer, editor, contributor, and essayist, as well as a novelist and poet with nearly twenty years of experience. A seasoned publishing professional, she's worked for newspapers, magazines and book publishers in content digitization, editorial, acquisitions and intellectual property. Sara has been an invited speaker at a Careers in Publishing & Authorship event at Michigan State University and a Reading and Writing Instructor at Sylvan Learning Center. She has an MBA degree with a concentration in Marketing and an MA in Clinical Mental Health Counseling, graduating with a 4.2/4.0 GPA. She is also a member of Chi Sigma Iota and a 2020 recipient of the Donald D. Davis scholarship recognizing social responsibility. Sara is certified in children's book writing, HTML coding and social media marketing. Her fifth book, PTSD: Healing from the Inside Out, was released in September 2019 and is available on Amazon. You can find her others books there, too, including Narcissistic Abuse: A Survival Guide, released in December 2017.
Amgen’s drug patent upheld and Novartis’s copycat version is denied.
Three of the top pharmaceutical companies have entered agreements to pay the state of California nearly $70 million to settle allegations that they “delayed drugs to keep prices high” according to California Attorney General Xavier Becerra. Most of the funds will come from Teva Pharmaceuticals ($69 million) for paying to delay a generic for Provigil,
New England Coffee Company’s Hazelnut Crème label is misleading, according to lawsuit.
Woman who has been a legal secretary for 25 years files a suit against two law partners.
Beaches have to be closed down in the final weeks of summer due to an oil spill at a steel plant near Portage, Indiana.
Jonas Kilpatrick, son of the former mayor of Detroit, Kwame Kilpatrick, posts a video on Facebook begging President Trump for his father’s release.
Novartis manipulated data to win approval for its spinal muscular atrophy treatment.
Connecticut is joining in on an investigation into JUUL’s marketingn efforts.
The Trump Administration follows the lead of some states and restricts short-term opioid use to seven days.
Cardinal Health, McKesson, and AmerisourceBergen have proposed paying $10 billion to settle all claims that they contributed to the opioid crisis. All three opioid distributors have been hit hard with claims that they did not do enough to flag and discontinue shipping large, suspicious orders of addictive drugs. The companies made the verbal proposal with